William Blair downgraded Neumora Therapeutics (NMRA) to Market Perform from Outperform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Johnson & Johnson discontinues depression program for aticaprant
- Douglas Tsao Recommends ‘Buy’ for Neumora Therapeutics Due to Navacaprant’s Market Potential and Differentiated Pharmacology
- Neumora Therapeutics downgraded to Neutral from Buy at Guggenheim
- Cautious Hold Rating on Neumora Therapeutics Amid Efficacy Concerns and Clinical Trial Setbacks
- Neumora Therapeutics downgraded to Hold from Buy at Stifel